The estimated Net Worth of Cyrus Harmon is at least 15.2 百万$ dollars as of 29 July 2024. Dr Harmon owns over 5,000 units of Olema Pharmaceuticals stock worth over 9,270,832$ and over the last 4 years he sold OLMA stock worth over 5,271,879$. In addition, he makes 657,991$ as CTO & Director at Olema Pharmaceuticals.
Dr has made over 24 trades of the Olema Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of OLMA stock worth 77,850$ on 29 July 2024.
The largest trade he's ever made was selling 30,000 units of Olema Pharmaceuticals stock on 31 January 2024 worth over 383,700$. On average, Dr trades about 13,227 units every 39 days since 2020. As of 29 July 2024 he still owns at least 751,283 units of Olema Pharmaceuticals stock.
You can see the complete history of Dr Harmon stock trades at the bottom of the page.
Dr. Cyrus L. Harmon Ph.D. is the CTO & Director at Olema Pharmaceuticals.
As the CTO & Director of Olema Pharmaceuticals, the total compensation of Dr D at Olema Pharmaceuticals is 657,991$. There are 1 executives at Olema Pharmaceuticals getting paid more, with Dr. Sean P. Bohen M.D., Ph.D. having the highest compensation of 999,300$.
Dr D is 50, he's been the CTO & Director of Olema Pharmaceuticals since . There are 5 older and 3 younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
Cyrus's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over 60,548,717$ worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth 82,289,865$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、G. Walmsley Graham、Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of 1,893,968$. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth 35,808,000$.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: